1. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
   Ha-Jeong Kim et al, 2016, Scientific Reports CrossRef
2. Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies
   Nele Van Der Steen et al, 2019, Targeting Cell Survival Pathways to Enhance Response to Chemotherapy CrossRef
3. HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation
   Anna Spina et al, 2015, Biomedicines CrossRef
4. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers
   Kaustubh A. Gawde et al, 2018, Colloids and Surfaces B: Biointerfaces CrossRef
5. Monitoring of ovarian cancer cell invasion in real time with frequency-dependent impedance measurement
   Chun-Min Lo et al, 2016, American Journal of Physiology-Cell Physiology CrossRef
6. Ockham’s razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer
   Giulia M. Stella et al, 2016, Journal of Translational Medicine CrossRef
7. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer
   Kim Moran-Jones, 2016, Molecular Diagnosis & Therapy CrossRef
8. Combined Expression of HGFR with Her2/neu, EGFR, IGF1R, Mucin-1 and Integrin α2β1 Is Associated with Aggressive Epithelial Ovarian Cancer
   Bastian Czogalla et al, 2022, Biomedicines CrossRef
9. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models
   Antonis Koussounadis et al, 2016, BMC Cancer CrossRef
10. First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Vicki L. Keedy et al, 2018, Investigational New Drugs CrossRef
11. cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
    Nele Van Der Steen et al, 2015, Cancers CrossRef
12. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance
    Enze Li et al, 2016, Tumor Biology CrossRef
13. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells
    Benoît Thibault et al, 2017, Journal of Ovarian Research CrossRef
14. Retracted: MicroRNA‑224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1
    Shuo Geng et al, 2016, Journal of Cellular and Molecular Medicine CrossRef
15. LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET
    Belén Mezquita et al, 2016, Molecular Carcinogenesis CrossRef
16. Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data
    Zhe Zhang et al, 2016, Scientific Reports CrossRef
17. Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics
    An Tong et al, 2023, Frontiers in Genetics CrossRef
18. E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
    Michaela Poliaková Turan et al, 2024, Cancer Research Communications CrossRef
19. INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models
    Kim Moran-Jones et al, 2015, Scientific Reports CrossRef
20. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
    Xiufeng Jiang et al, 2015, Oncotarget CrossRef
21. The role of MET in chemotherapy resistance
    Georgina E. Wood et al, 2021, Oncogene CrossRef